Wolfe Research Begins Coverage on Medline (NASDAQ:MDLN)

Wolfe Research began coverage on shares of Medline (NASDAQ:MDLN) in a research note issued on Monday. The brokerage set an “outperform” rating and a $47.00 price target on the stock. Wolfe Research’s price objective suggests a potential upside of 15.99% from the company’s current price.

MDLN has been the subject of several other research reports. Royal Bank Of Canada started coverage on shares of Medline in a research report on Monday. They set an “outperform” rating and a $47.00 target price for the company. Cowen began coverage on Medline in a research note on Monday. They issued a “buy” rating on the stock. Leerink Partners assumed coverage on Medline in a research note on Monday. They issued an “outperform” rating and a $48.00 price target for the company. Evercore ISI initiated coverage on shares of Medline in a research note on Monday. They set an “outperform” rating and a $50.00 price objective on the stock. Finally, The Goldman Sachs Group set a $49.00 price objective on shares of Medline and gave the company a “buy” rating in a report on Monday. Eighteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Medline presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.25.

Medline Stock Down 1.8%

MDLN opened at $40.52 on Monday. Medline has a fifty-two week low of $34.89 and a fifty-two week high of $45.50.

Insider Activity

In related news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the sale, the insider directly owned 4,806,160 shares in the company, valued at $136,350,759.20. This trade represents a 55.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Andrew J. Mills bought 2,586,206 shares of Medline stock in a transaction that occurred on Thursday, December 18th. The stock was bought at an average cost of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the purchase, the director owned 2,586,206 shares in the company, valued at approximately $74,999,974. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies started coverage with a “Buy,” highlighting Medline’s ~$25 billion supply-chain scale as a durable competitive advantage that supports growth and margin expansion. Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
• Positive Sentiment: TipRanks coverage of new sell‑side initiations (e.g., J.P. Morgan) emphasizes Medline’s prime‑vendor position, branded mix shift and margin expansion runway — factors analysts say justify a premium valuation. Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation
• Positive Sentiment: Multiple outlets report a broad set of bullish analyst initiations after the IPO (Buy/Overweight ratings and constructive price targets), which is amplifying positive sentiment and buying interest. Analysts initiate Medline with bullish ratings after blockbuster IPO
• Positive Sentiment: Media and TV coverage — including praise from commentators such as Jim Cramer — is raising retail and institutional visibility for MDLN, supporting near‑term momentum. Jim Cramer Medline: “It’s a Terrific Company”
• Neutral Sentiment: A valuation note points out shares are trading near a DCF estimate after the recent moves, suggesting limited near‑term upside unless execution or margin beats occur — a reminder that much of the positive view is already priced in. Medline (MDLN) Valuation Check As Shares Trade Near DCF Estimate After Recent Moves

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.